Advances in research on circadian rhythms and colorectal cancer Authors: Lingjuan Jia, Meng Zhu, Xiaqiu Wu, Weifang Zheng, Yongsheng Zhang, Jing Xiao Published: 2026 ABSTRACT AbstractWith the change of people's dietary habits and irregular lifestyle, such as frequent high-fat diets and overtime work, the prevalence of colorectal cancer nowadays is increasing year by year. Due to the long latency period of colorectal cancer, how to prevent the high-risk factors associated with the development of colorectal cancer is one of the hotspots of research. Studies have shown that there is a significant correlation between circadian rhythms and colorectal cancer, and it is possible to prevent and treat colorectal cancer from the perspective of circadian rhythms to reduce its incidence, recurrence and prolong the survival cycle of patients. In this paper, we review the studies related to circadian rhythms and colorectal cancer.Keywords: Circadian rhythm, Colorectal cancer, Chronotherapy, Gene Introductory Colorectal cancer (CRC), one of the common malignant tumors of the digestive tract, has ranked second in the world in terms of mortality rate as its incidence rate increases year by year [1]. The global incidence rate of colorectal cancer in 2020 was 1,880,000 and the number of deaths was 915,880 [2]. According to the 2020 China cancer statistics report, the incidence and mortality of colorectal cancer in china ranked second and fifth among all malignant tumors, including 555000 new cases and 286000 deaths. [3]. Colorectal cancer is evolved from colorectal adenoma [4–6], colorectal adenoma is the basis of morphologic changes in the pre-colorectal cancer stage, and the "adenoma-carcinoma sequence" plays an important role in the development of colorectal cancer, with a latency period of 10–15 years. Therefore, how to prevent colorectal cancer has become an urgent problem. In recent years, many studies have found that circadian rhythm changes can increase the risk of colorectal cancer [7], so this paper discusses the correlation between circadian rhythm genes and colorectal cancer. Circadian rhythms and diseases Nocturnal circadian variations are inherent in nature's 24-h cyclic cycle, which occurs mainly in various physiological activities of our body and is regulated by the internal circadian clock [8]. The suprachiasmatic nucleus (SCN) of the hypothalamus, known as the endogenous pacemaker, is the location of the most important Circadian rhythm genes in mammals [9]. In higher photosensitive organisms, circadian rhythm is a collection of functional systems jointly regulated by photoreceptor neurons, endocrine system and gene time oscillation expression, which enables organisms to form circadian rhythm from gene expression and cellular metabolism at the micro level to the macro biological behavior level [10]. Circadian rhythms are associated with many diseases, for example, abnormal expression can lead to cardiovascular diseases by participating in inflammatory and metabolic processes in humans [11]; genetic variation can increase the prevalence of breast cancer and affect its prognosis [12] and down-regulation of gene expression leading to disruption of rhythms can promote hepatocellular carcinoma [13]. In mammals, the major circadian oscillators are constructed from transcriptional-translational feedback loops, which are responsible for generating and maintaining daily oscillations in their own transcriptional and protein levels [14], and the main mechanisms [15] by which this occurs are shown in Fig. 1. Mechanism of the circadian rhythm. Note: BMAL1: muscle aromatic hydrocarbon receptor nuclear transporter-like protein 1; CLOCK: clock circadian regulator; E-box: E-response element; CRY: cryptochrome; PER: circadian protein; CCGs: clock control genes. bMAL1 and CLOCK genes bind to DNA elements containing the E-box motifs and induce expression of the transcriptional repressor cryptorchrome (CRY) and periodic (PER) genes.The CRY and PER protein complexes reduce the expression activity of CLOCK-BMAL1, thereby repressing their own transcription. When CRY and PER proteins are degraded, BMAL1-CLOCK activity can be restored again Circadian rhythm and colorectal cancer In recent years, it has been found that mammalian circadian genes are closely related to the physiological and pathological development of many diseases [16], especially with the correlation with tumors [17, 18], and colorectal cancer is one of the cancers that are closely related to the dysfunction of circadian clock [19]. Circadian clock is a key control node for tumor progression [20], BMAL1 gene can induce CRC metastasis by stimulating exosomal secretion [21], and Per1, Per2, Rev-Erb α, and BMAL1 genes, etc. undergo significant transcriptional changes with circadian rhythm time [22]. Circadian rhythm genes can affect various cellular activities associated with cancer progression, such as cell cycle, DNA damage repair, proliferation and apoptosis, etc. through their aberrant expression. Moreover, the intestine has been found to have circadian rhythms even before the discovery of circadian clock rhythms [23, 24]. Narducci et al. [25] recorded the motility activities of the transverse, descending and sigmoid colon in 24 healthy volunteers before and after meals, and before and after bedtime using a colonoscopic positioning catheter. The results showed low colonic motility activity before meals and less during sleep; motility indices increased significantly after meals and upon awakening in the morning. These studies suggest that colorectal cancer may be related to the circadian rhythm in its host. Circadian genes and colorectal cancer PER gene family (Per1, Per2 and Per3) Period genes (Per1, Per2 and Per3) are present in most cells and are one of the clock gene components in the transcription-translation feedback loop. They can control cell proliferation, metabolism and many key functions, such as recognition and repair of DNA damage, etc. Abnormalities in their expression have been associated with colorectal cancer development and progression. Per1 gene is an important core clock factor, which is closely related to the cell division cycle and plays an important role in circadian rhythms.Overexpression of Per1 sensitizes human cancer cells to DNA damage-induced apoptosis; on the contrary, low-expression of Per1 attenuates apoptosis [26]. Ansell et al. [27] found that low-expression of Per1 has a pro-carcinogenic effect and can increase the growth of cancer cells in vitro and tumors in vivo; its high expression has a tumor-suppressive effect that reduces the proliferation and growth of tumor cells, but this effect can only be exerted at specific time points during the day by enhancing the circadian amplitude of the growth peak. Per2 gene is a core clock gene expressed mainly in colonic epithelial cells and plexus, one of the molecular bases of colonic motility biorhythmicity, responsible for adjusting the period and amplitude of colonic motility rhythms and by adjusting the excitatory and inhibitory nerves of enteric nerve terminals. It also plays a key role in the inhibition of tumor growth [28]. The association of the Per2 gene with colorectal cancer has been shown to be tightly linked to β-linker protein-induced intestinal cancer mutations in mice, which contribute to the mutation of the Per2 gene, as well as hindering its expression [29]. In addition, mutations in the Per2 gene increase the level of β-linker proteins in the cells of the intestinal wall, which further stimulates the production of colon polyps (precancerous lesions), which can have an impact on intestinal motility. Per3, a protein gene that can be regulated during the day and night in the form of tan or yellow granules, has an important influence on cell cycle, growth and differentiation. It is involved in DNA damage and repair processes and regulates tumor generation and progression. He Yiyang [30] found that in normal tissues, the expression of per3 showed moderate-strong positivity and staining of both nucleus and cytoplasm, with a 100% positivity rate, while in colorectal cancer tissues it showed weak positivity. The difference in expression between the two was statistically significant and meaningful. The expression level of Per3 in colorectal cancer tissues depends on the presence of lymph node metastasis, clinical stage of the tumor, level of differentiation, and depth of tumor invasion, and is not directly related to factors such as age and gender.Oshima et al. [31] used a real-time quantitative reverse transcription-polymerase chain reaction to examine the correlation between the cancer cells obtained from 202 patients with treatment-naïve colorectal cancer as well as related properties of nearby healthy mucosal samples and determined the relative expression levels of circadian genes in the specimens. The results of the study revealed that the expression levels of Per1 and Per3 genes were significantly lower in colorectal cancer tissues compared to normal mucosa, and this low expression status may be an important reference for predicting the prognosis of colorectal patients. In addition, a study [32] revealed how the Per3 protein gene reduces the resistance of colorectal cancer stem-like cells (CSCs) to chemotherapy as well as their self-repair function by blocking the messaging between Notch and β-catenin, which has an important impact on the aspect of maintaining the stemness of CSCs. CLOCK gene CLOCK genes are one of the core genes regulating circadian rhythms, and its expression is different in tumor and normal tissues. It has been found to have a close correlation with the occurrence and development of tumors, and colorectal cancer is one of them. By analyzing colorectal cancer tissues, Bozan Chen [33] found that the expression level of CLOCK gene was significantly higher in human colorectal tumor tissues compared with paired normal intestinal mucosal tissues.Alhopuro [34] attempted to investigate how CLOCK gene affects colorectal cancer. They studied 101 CRCs with MSI (genetic instability caused by defects in the DNA mismatch repair system) and applied it to the eight thymidine (T9) coding microsatellites of exon 9 of the CLOCK gene. The results of the study showed that most MSI CRCs have mutations in somatic CLOCK, and that these mutations cause a decrease in the level of CLOCK expression. A reported study found [35] that the identification of 2 single nucleotide polymorphisms (SNPs) in the CLOCK gene was significantly associated with CRC overall survival, and polymorphisms in the CLOCK gene may be able to serve as an independent marker of CRC prognosis. However, the detailed rationale for colorectal cancer still needs to be thoroughly investigated, which may implicate the regulation of many cellular activities. However, as far as the current data are concerned, CLOCK deletion confers a cancer-prone cellular phenotype. BMAL1 gene BMAL1, also known as MOP3, is a core driver of the mammalian Circadian rhythm, located on chromosome 11, and is considered to be the only irreplaceable clock gene that regulates rhythmic behavior. In order to further clarify the role of BMAL1 gene in colorectal cancer, Liu Jinglin et al. [36] tested the colorectal specimens of a colorectal cancer patient without metastasis, and from the results, it was concluded that the number of BMAL1 lymphocytes in paraneoplastic area was significantly higher than that of the control group. Epithelial mesenchymal transition (EMT) is one of the important processes in colorectal cancer invasion and metastasis, and BMAL1 regulates the activation of the EMT process as well as the migratory and invasive behaviors of colorectal cancers. EMT can drive distant metastasis of colorectal cancers, and c-Myc (proto-oncogene), which is one of the most important regulators of EMT, contributes to the process of metastasis of CRC and other carcinomas, and it was also found by study [37] that c -Myc is highly expressed in most colorectal cancers, and BMAL1 gene can not only activate the up-regulation of c-Myc through the MAPK signaling pathway, but also has been shown to be a target of aberrant Circadian rhythm expression [38]. Therefore, high expression of BMAL1 gene can reduce the survival rate of colorectal cancer patients. Tumor cells grow and multiply rapidly, require more nutrients, and the rate of glycolysis in vivo is accelerated, so glycolysis is an important target for treating tumor development and has strong therapeutic potential. In a study [39], through the analysis of primary fibroblasts isolated from normal and colorectal cancer tissues, it was found that BMAL1 deletion disrupted the circadian rhythm, led to the downregulation of the expression of glycolysis related gene HKDC1(glycolytic gene), reduced glycolytic activity, and thus slowed down the growth process of colorectal cancer. Cryptochrome gene family (CRY1 and CRY2) Cryptochrome genes (CRY1 and CRY2) encode circadian proteins that play a crucial role in the regulation of biological oscillators. Qiu Mengjun et al. [40] utilized the Cancer Genome Atlas Database to investigate the expression of 14 circadian genes across six types of abdominal malignant tumors. They found that these genes, including Per1, Per2, Per3, Cry1, Cry2, Timeless, BMAL1, NR1D2, DEC1, DEC2, and RORA, were consistently downregulated in tumor tissues compared to the surrounding healthy tissues (with all P values less than 0.05, indicating statistical significance). Moreover, the expression levels varied across different types of abdominal cancers, suggesting a diverse impact of circadian gene dysregulation on different tumor types.Similarly, Mazzoccoli et al. [41] studied the mRNA expression levels of Cry1 and Cry2 in 144 patients with colorectal cancer and their paired normal tissues. Their research revealed a positive correlation between the expression of Cry1 and Cry2, with both showing significant changes in colorectal cancer. These alterations may influence tumor cell proliferation and apoptosis, particularly in elderly and female patients, as well as those with cancer located in the transverse colon. Notably, changes in Cry1 and Cry2 expression were strongly associated with overall survival in colorectal cancer patients.These findings suggest that the expression patterns of cryptochrome genes could play a pivotal role in the clinical manifestations, prognosis, and treatment response of colorectal cancer. The changes in Cry1 and Cry2 expression, along with their interactions within the genetic landscape of colon cancer cells, may underpin phenotypic differences observed in the disease. These differences could potentially influence disease behavior, patient survival, and the response to chemotherapy. The nuclear receptor family REV-ERBs, which participate in circadian transcriptional/translational feedback loops as repressors of transcription, are essential components of the circadian clock and have important roles in metabolism, inflammatory responses, and neurons, but the specific mechanisms that maintain the rhythmicity of the circadian clock in molecular terms are not known at this time. It has been found [42]that REV-ERBs are essential and play an important role in BMAL1 rhythm (REV-ERB α and β are required for Bmal rhythmicity in fibroblasts), and that there is a correlation between aberrant BMAL1 expression and colorectal cancer. The ligands for REV-ERB α and REV-ERB β are hemoglobin (which is a pro-oxidant) and studies have found that dietary heme forms a highly cytotoxic factor that damages the colorectal mucosa [43], leading to excessive compensatory proliferation of epithelial cells, which can lead to colorectal cancer. Lee et al. [44] found that heme iron intake led to a more than two-fold increase in the relative risk of proximal colorectal cancer by using a food frequency questionnaire from the Women's Health Study, showing a positive correlation, but whether it is associated with REV-ERBs nuclear receptor family, the exact mechanism remains to be further investigated. Circadian rhythm and diagnosis and treatment of colorectal cancer Chronotherapy is now a more commonly used therapeutic tool to intervene in colorectal cancer by adapting its treatment to circadian rhythms, also known as cancer chronotherapy, which aims to regulate exogenous metabolism and cellular drug responses through endogenous circadian clock rhythms [45]. Pharmacokinetic studies of drugs have found that circadian rhythms are also closely correlated with them, and administration of drugs at different times of the day can lead to different outcomes [46]. It is not only the time of day when the drug is administered that plays a role, but also the pH of the stomach and the function of gastrointestinal motility at that time the latter two of which have also been found to have circadian rhythms and play a synergistic role. Nowadays, the use of anticancer drugs is supplemented with chronotherapy, which is beneficial for prolonging the survival cycle of cancer [47]. The combination of oxaliplatin and 5-fluorouracil (FU) is now used as the most commonly used chemotherapeutic agent for the treatment of colorectal cancer [48]. Oxaliplatin has a long half-life, and it has been found that the timing of oxaliplatin administration affects its toxicity and action efficacy, Lévi timed the treatment schedule documented oxaliplatin against metastatic colorectal cancer, forming a new approach to the combination therapy of this disease, improving the survival of the patients and varying with the time of administration. The sensitivity of colorectal cancer cells to oxaliplatin in vitro and in vivo can be enhanced by up-regulation of BMAL1, but the exact mechanism is not yet clear [49]. Some published clinical trials of colorectal cancer and circadian rhythm are shown in Table 1. Table 1clinical trials of colorectal cancer related to circadian rhythmrial YearSample SizeMain Drug RegimenPrimary Endpoint and Results1990 (Oxaliplatin Chronotherapy Phase I)23OxaliplatinChronotherapy significantly enhanced oxaliplatin efficacy, reduced hematologic and neurotoxicity, and improved the therapeutic index [50]1992(Expanded Phase II Clinical Trial)935-fluorouracil, Leucovorin, OxaliplatinChronotherapy improved efficacy (58% response rate) and reduced toxicity, especially mucositis [51]1993 (Phase II Clinical Trial)30OxaliplatinChronotherapy regimen enhanced the antitumor activity of oxaliplatin [52]1994 (Phase I Clinical Trial)85-fluorouracil, Folinic AcidThe effectiveness of chronotherapy may highly depend on the specific infusion pattern [53]1994 (Clinical Pharmacology Trial)9Oxaliplatin, 5-fluorouracil, LeucovorinChronotherapy increased drug concentration, significantly improving the efficacy-to-toxicity ratio [54]1994 (Randomized Controlled Clinical Trial)92Oxaliplatin, 5-fluorouracil, LeucovorinChronotherapy significantly enhanced efficacy and reduced toxicity, particularly severe mucositis [55]1995 (Phase I-II Clinical Trial)355-fluorouracil, LeucovorinChronotherapy significantly reduced 5-FU toxicity, enabling higher doses of treatment [56]1997 (Phase I Clinical Trial)345-fluorouracil, LeucovorinChronotherapy significantly improved antitumor activity, laying the foundation for subsequent combination therapy with oxaliplatin [57]1997(International, Multicenter, Randomized, Phase III Trial)186Oxaliplatin, 5-Fluorouracil, LeucovorinChronotherapy significantly improved the antitumor efficacy in metastatic colorectal cancer while drastically reducing chemotherapy-related toxicity [58]1999 (Multicenter, Phase II Clinical Trial)90Oxaliplatin, 5-Fluorouracil, LeucovorinLarge-scale, multicenter studies confirmed that chronotherapy allows safe administration of intensified drug doses, achieving high response rates [59]1999 (Single-arm, Phase II Clinical Trial)56Hepatic artery fluorouridine and venous 5-FluorouracilChronotherapy improved drug tolerance and dose intensity [60]2000 (Phase II Clinical Trial)21Cisplatin or Oxaliplatin, 5-Fluorouracil, Folinic AcidChronotherapy strategies may produce different efficacy outcomes depending on the drug combination, highlighting the unique role of specific drugs in particular cancer types [61]2000(Rest-Activity Rhythm Study)2005-Fluorouracil, Leucovorin, OxaliplatinChronotherapy can improve efficacy without affecting dose intensity [62]2002 (High-dose 5-FU/LV Chronotherapy Phase II)100Fluorouracil, L-LeucovorinChronotherapy safely enables high-intensity chemotherapy, significantly improving therapeutic outcomes [63]2004 (Multicenter, Randomized, Phase III Clinical Trial)320Mitomycin C, 5-FluorouracilFixed-rate nocturnal infusion failed to improve efficacy and increased toxicities, highlighting the need for precise drug adjustment [64]2005 (Randomized Controlled Study)375-Fluorouracil, Leucovorin,CarboplatinDirect comparison between standard and chronotherapy regimens provided clinical evidence on the impact of different drug schedules on toxicity [65]2005 (Carboplatin Combined with Chronotherapy Phase II)725-Fluorouracil, Folinic Acid, CarboplatinChronotherapy regimen significantly improved efficacy, with manageable toxicity, showing superiority as a first-line treatment option [66]2005 (BE-1603 Phase I-II)36Irinotecan, 5-Fluorouracil, Folinic Acid, CarboplatinThe chronotherapy-based four-drug combination regimen showed significant antitumor activity and was safe and feasible [67]2006 (EORTC 05962 Phase III)5645-Fluorouracil, Leucovorin, OxaliplatinMale patients showed extended survival, with significantly reduced toxicity [68]2006 (Phase II Clinical Trial)77Irinotecan, 5-Fluorouracil/Leucovorin, OxaliplatinChronotherapy-based chemotherapy improved efficacy and survival in patients with metastatic colorectal cancer [69]2008(Multicenter, phase II clinical trial)71Oxaliplatin, capecitabineThe sequential combination regimen has considerable disease control ability and is well tolerated [70]2009 (ORTC 05963 Phase III Clinical Trial's Auxiliary Study)1305-Fluorouracil, Leucovorin, OxaliplatinRest-activity circadian rhythm was an independent predictor of quality of life and survival in metastatic colorectal cancer patients [71]2011(Prospective Phase II Clinical Trial)56Cetuximab, Irinotecan, Oxaliplatin, 5-FluorouracilCetuximab combined with chronotherapy regimen was safe, effective, and well-tolerated [72]2011 (Based on EORTC 05963 Phase III Clinical Trial)5565-Fluorouracil, Leucovorin, OxaliplatinChronotherapy can personalize and optimize treatment, improving hematologic tolerance and efficacy [73]2020 (EORTC 05011 Phase II)1935-Fluorouracil, Leucovorin, Oxaliplatin (chronoFLO)Irinotecan toxicity exhibited significant gender-dependent circadian rhythm [74] clinical trials of colorectal cancer related to circadian rhythm The metabolism, toxicity and efficacy of a variety of commonly used chemotherapeutic drugs for colorectal cancer show certain circadian rhythm characteristics. When administered at a specific time of day, the drug tolerance of patients is often significantly improved, which may reduce the incidence of adverse reactions while maintaining the efficacy. The optimal administration time of various drugs is shown in Table 2. Table 2The Optimal administration time of drugsDrug RegimenOptimal administration timeOxaliplatinThe infusion rate peaked at 16:00, and decreased to the lowest at night and early morning [50]5-fluorouracilThe infusion rate peaked at 04:00 [56]Folinic AcidGenerally used in combination with oxaliplatin and 5-fluorouracil, the infusion rate peaked at 16:00 [51, 53]5-fluorodeoxyuridineThe infusion rate peaked at 04:00–05:00 and reached the lowest value in the afternoon [60]CisplatinThe infusion rate peaked at 16:00–20:00 [61]IrinotecanGender related, the infusion rate peaks around 9:00 for males and between 13:00 and 17:00 for females [74]CapecitabineAdministered separately in the morning and at night, and the dose administered at night accounted for a larger proportion [70, 75–77] The Optimal administration time of drugs The core clinical value of circadian rhythm for colorectal cancer has been fully verified: its most clear and consistent contribution is to significantly reduce chemotherapy toxicity, especially 5-fluorouracil-related oral mucositis and oxaliplatin related peripheral neurotoxicity. This directly widens the safety window of treatment, improves the tolerance and quality of life of patients, and provides a synergistic and detoxification strategy with both physiological basis and evidence-based basis for clinical practice. It has been found that a prolonged one fast at night can have a positive effect on carcinogenic metabolic processes and cancer prognosis and can reduce its prevalence [78]. The circadian gene network plays an important role in energy homeostasis in mammals, and mutations in circadian genes can cause alterations in feeding rhythms, such as hyperphagia and anorexia, which can lead to a range of disorders such as obesity and metabolic syndrome [79]. There is a close relationship between circadian rhythm and nutritional pathways. High fat diet can affect the normal function of circadian rhythm by impairing the nuclear receptor network that regulates circadian rhythm genes [80]. Numerous studies [81, 82] have found that poor diet can increase the prevalence of colorectal cancer, such as high consumption of red meat and processed meat products, high-fat diet, and reduced fiber intake. Circadian rhythms can respond to acutely activated or repressed transcriptional responses through feeding-dependent gene expression [83]. For example, feeding leads to low mRNA expression of the Per1 gene, which leads to high mRNA expression of Per2 that affects transcription, ultimately influencing disease progression. Modifications in dietary structure and habits can influence circadian rhythms and reduce the prevalence of colorectal cancer. Earlier studies have found that time-restricted feeding and rhythmic eating can enhance circadian direct target gene expression and amplitude of oscillations, thereby enhancing rhythmic transcription, and that alternation of feeding and fasting can influence the circadian cycle to maintain human health. In species with mature circadian rhythms, circadian oscillators have developed a personalized feeding and fasting feeding cycle that is compatible with the circadian rhythm on a 24-h basis [84], and dietary therapies are also a means and method of colorectal cancer prevention and treatment. In addition to diet, others such as sleep are associated with circadian rhythms [85] and colorectal cancer [86]. There are various cytokines involved in cancer development, which also includes interleukin 1β (IL-1β). It was found that IL-1β not only promotes cancer development in the tumor microenvironment, but also follows a circadian rhythm [87]. Not only that, Lauren et al. [88] through a questionnaire on the history of night shift work hours and working hours of 1995 African American women, the results of the study found that prolonged night shift work increases the risk of colorectal cancer. Therefore, establishing good sleep habits can also reduce the incidence of colorectal cancer. Mitochondria also have circadian rhythms [89], and mitochondrial dynamics and oxidative metabolism are important targets for transcription of circadian genes [90]. Many substances involved in metabolic pathways have been found to have circadian rhythms [91], and the mitochondrial network is characterized by the expression of circadian genes through key rate-limiting enzymes [92], such as protein deacetylase (SIRT1) and nicotinamide phosphoribosyl transferase (redox-sensing enzyme) [93] that can communicate metabolic status to the cytosolic circadian oscillator through nutrient dependence. The fission–fusion cycle of mitochondria is controlled by dynamin-related protein 1 (Drp1), which is synchronized with a genetic rhythm clock; Drp1 is a key mediator of mitochondrial fission, and circadian oscillations in turn depend on circadian modifications of Drp1 [94]. Mitochondria and its related proteins and mediators may become an important tool in the treatment of colorectal cancer through the circadian pathway, which can not only reduce the disease recurrence rate, but also prolong the survival of patients. Summary Circadian rhythm exists not only in organisms, but also in all things in the world. The alternation of day and night takes place every second, in a state of relative quiescence and absolute motion. Various metabolic activities in the human body change with the changes of circadian rhythm, which can predict whether the changes of various metabolism in the human body are normal, which is conducive to the prevention and treatment of diseases. Tumor development is never generated overnight, but is often the result of the accumulation of harmful risk factors and the gradual development of the body's metabolic abnormalities. Circadian rhythms have now been shown to correlate with colorectal cancer and are used in the treatment of the disease. Circadian rhythms may be involved in cell proliferation and tumor growth, and are responsible for predictable changes in the tolerance and efficacy of anticancer drugs. Taking anticancer drugs in combination with chronotherapy (i.e., circadian rhythm-based treatment regimens) can significantly prolong the survival cycle of colorectal cancer patients. The combination of circadian drug administration or dietary sleep patterns may offer new possibilities to optimize current cancer treatment regimens and to optimize the development of new anticancer or supportive medications. Currently, researchers are continuing to explore how circadian rhythms can be utilized to improve the quality of life of colorectal cancer patients, increase their survival rates and reduce the risk of recurrence. Most of the existing schemes are based on the "average" circadian rhythm. The future trend is to combine individual biomarkers (such as the rhythm monitored by the body motion recorder, clock gene expression) for personalized time administration and how to integrate the principle of time therapy into the new scheme based on targeted therapy and immunotherapy. Acknowledgements Not applicable. Authors’ contributions JLJ was responsible for writing the first draft, ZM and XJ was responsible for collecting information and data, WXQ and ZWF were responsible for revising the manuscript, and ZYS was responsible for final revisions and review. Funding This work was supported by Natural Science Foundation of Zhejiang Provincial (LZ22H270001). Data availability Data sharing is not applicable to this articleas no new data were created or analyzed in this study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data sharing is not applicable to this articleas no new data were created or analyzed in this study.